The glyoxalase system i s , therefore, o f increasing i n t e r e s t as a t a r g e t f o r cancer chemotherapy.
The glyoxal ase system catalyses the conversion o f methylglyoxal t o D-lactate v i a the intermediate S-Dl a c t o y l g l u t a t h i o n e [l] . The a c t i v i t i e s o f glyoxalaae enzymes, g l oxalase I (EC 4.4.1.5) and glyoxalase I1
(EC 3.1.2.63(, have been studied i n tumour tissues t o gain evidence f o r the presence o f c h a r a c t e r i s t i c a c t i v i t i e s i n malignant tissues and propose the glyoxalase enzymes as prospective targets f o r novel anti-tumour agents [2].
The a c t i v i t y o f glyoxalase I i n murine and human tissues was found t o be higher, lower o r about the same as t h a t i n non-tumour tissues.
The a c t i v i t y o f glyoxalase I1 i n human and murine tumours was markedly lower than i n non-tumour t i s s u e [3] . Glyoxalase I may be a t a r g e t f o r novel anti-tumour agents: glyoxalase I i n h i b i t o r s delivered i n t o tumour c e l l s are cytotoxic [4] . The glyoxalase intermediate, S-D-lactoylglutathione induces growth a r r e s t and t o x i c i t y i n human tumour c e l l s i n c u l t u r e [5, 6] .
The glyoxalase system i s , therefore, o f increasing i n t e r e s t as a t a r g e t f o r cancer chemotherapy.
Further characterisation o f glyoxalase a c t i v i t i e s i n tumour and non-tumour tissues may p r e d i c t the r e l a t i v e s e n s i t i v i t y o f d i f f e r e n t tumour types t o glyoxalase-related chemotherapy.
W e have assayed glyoxalase a c t i v i t i e s i n 3 nonmalignant p r o l i f e r a t i n g human c e l l s and 28 human tumour c e l l l i n e s (mainly cancers o f urological o r i g i n , two (n = 21) (n = 3) (n = 37) -0.50
(prol i f e r a t i n g ) (prol i f e r a t ing) Fig. 1 . Glvoxalase a c t i v i t i e s i n maliqnant and nonmaliqnant human c e l l l i n e s . c e l l l i n e s derived from normal urothelium and one o f transformed f i b r o b l a s t s .
These and other data from normal, quiescent tissues [3, 7] are shown (Fig. 1) .
Glyoxalase a c t i v i t i e s were assayed as described [5] . The mean c o e f f i c i e n t s o f variance (c.v.) f o r the survey o f the 31 human tumour c e l l l i n e s were 12.8% (glyoxalase I ) and 16.4% (glyoxalase 11), performed by i n v e s t i g a t o r F.M.A.
( Table 1) Screening o f glyoxalase I a c t i v i t i e s i n tumours may p r e d i c t the s u s c e p t i b i l i t y t o these agents. S-2-Hydroxyacylgl utathione derivatives induce growth a r r e s t and t o x i c i t y i n tumour c e l l s but the associated receptor appears not t o be glyoxalases [6] .
